Immunotherapy

February 20, 2020February 20, 2020

Adding Provenge to Xtandi, Zytiga Reduces Risk of Death by 45% in mCRPC Patients, Data Shows

News

Adding the immunotherapy Provenge (sipuleucel-T) to a regimen containing the oral agents Zytiga (abiraterone acetate) or Xtandi (enzalutamide) significantly extends the lives of men with metastatic castration-resistant prostate cancer (mCRPC) in ... Read more

January 15, 2020January 15, 2020

Advaxis Seeks FDA Approval to Begin Phase 1 Trial of its ADXS-504 Immunotherapy for Prostate Cancer

News

Advaxis is seeking permission from the U.S. Food and Drug Administration (FDA) to start the first Phase 1 clinical trial of ADXS-504, a potential immunotherapy for prostate cancer. Cancer cells ... Read more

December 12, 2019

Blank Family Foundation Donates $1M to Mount Sinai for Prostate Cancer Research

News

The Arthur M. Blank Family Foundation has given $1 million to the Icahn School of Medicine at Mount Sinai‘s urology department to support research into prostate cancer. Together with an earlier foundation gift ... Read more

August 29, 2019

FDA Clears Way for Trial of Immunotherapy in Advanced Prostate Cancer, Scripps Research Says

News

The U.S. Food and Drug Administration (FDA) has signed off on a clinical trial that will test CCW702, an immunotherapy developed by Calibr at Scripps Research, as a possible treatment of ... Read more

August 9, 2018August 9, 2018

First Patient Advanced Prostate Cancer Treated with Harpoon Therapeutics’ HPN424

News

A Phase 1 clinical trial of Harpoon Therapeutics’ immunotherapy candidate, HPN424 for metastatic castration-resistant prostate cancer (mCRPC), has treated the first patient, according to the company. HPN424 uses the Harpoon’s TriTAC (Tri-specific T cell Activating Construct) platform. ... Read more

June 11, 2018

Sotio Starts Phase 1/2 Trial of DCVAC/PCa plus ONCOS-102 in Advanced Prostate Cancer

News

The first patient has enrolled in Sotio‘s Phase 1/2 clinical trial testing the immunotherapy DCVAC/PCa in combination with ONCOS-102 in men with advanced prostate cancer. The patient was enrolled in Prague, ... Read more

January 17, 2018

ProscaVax Reduced Tumor Growth in 70% of Prostate Cancer Patients, Early-stage Study Shows

News

OncBioMune‘s investigational cancer vaccine ProscaVax reduced tumor growth in 70% of prostate cancer patients included in a Phase 1a study. The immunotherapy candidate consists of a combination of the PSA protein ... Read more

November 9, 2017

SOTIO Completes Enrollment for Phase 3 Trial of DCVAC/PCa Immunotherapy

News

The Phase 3 trial evaluating the immunotherapy DCVAC/PCa in men with metastatic castration-resistant prostate cancer (mCRPC), has completed patient enrollment, according to trial sponsor, SOTIO. The treatment is being evaluated as ... Read more

September 25, 2017September 25, 2017

Inovio Advances New DNA-Based Antibody As Potential Therapy for Prostate Cancer

News

Inovio Pharmaceuticals reported that its experimental gene therapy-based antibody against prostate cancer has shown promising effects in early mouse studies of the approach, which combines advanced methods to combat cancer. ... Read more

September 8, 2017September 8, 2017

Aptevo Regains Rights to Prostate Cancer Therapy APVO414, Whose Results Improve After Delivery Method Tweaked

News

Aptevo Therapeutics has ended its partnership with MorphoSys AG for the development and commercialization of APVO414 as a treatment for metastatic castration resistant prostate cancer, or mCRPC. The termination means the company has ... Read more